1. ZS Pharma Appoints Martin Babler to Board of Directors

    ZS Pharma Appoints Martin Babler to Board of Directors

    COPPELL, Texas -- ZS Pharma , a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that Martin Babler, Chief Executive Officer ...

    Read Full Article

    Login to comment.

  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Sponsored Content
  2. Quotes

    1. Given Martin's significant track record with block buster medicines such as the launches of Rituxan and Xolair and in the preparation of the launches of Avastin and Lucentis, we are extremely pleased that he will be joining our Board to provide strategic advice around our global commercial initiatives for ZS-9.
  3. Topics Mentioned